B of A Securities Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $76
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad maintains a Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) but lowers the price target from $83 to $76.
May 31, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B of A Securities analyst Tazeen Ahmad maintains a Buy rating on Ultragenyx Pharmaceutical but lowers the price target from $83 to $76.
The Buy rating suggests continued confidence in Ultragenyx Pharmaceutical's prospects, but the lowered price target indicates some caution regarding its short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100